Hadassah

Hadassah and Boston Cardiologists Identify Factor Which Exacerbates Heart Failure

Thursday, Sep 27 2012

In a series of experiments, Dr. Ronen Beeri, Director of the Cardiovascular Research Center at the Hadassah Medical Center, and Dr. Robert Levine, Senior Physician at Massachusetts General Hospital in Boston, have demonstrated that mitral regurgitation augments the remodeling process occurring after a myocardial infraction which, in turn, exacerbates further heart failure.

They have also discovered that repairing the mitral regurgitation early enough may reverse these deleterious processes, while delayed repair may not. The two physicians have now begun to explore the cellular processes which cause the individual cells to fail. In what may hold promise for the future, they have utilized gene therapy techniques in a sheep model of heart failure to implant a gene for the Sarcoplasmic reticulum Ca (+2)-ATPase ( SERCA2a), which controls a key process in the cell's calcium signaling. The sheep which underwent gene therapy had upregulated levels of SERCA2a, which led to better function and lesser remodeling. They exhibited improved contractility, smaller heart volumes, and activation of cellular pathways that lead to better heart compensation.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More